Shots: The BLA submission is based on two studies assessing ABP 798 vs Rituxan which resulted in analytical, PK and clinical data showing no clinically meaningful differences between products In […]readmore
Tags : ABP 798
Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing […]readmore
Shots: The JASMINE study involves assessing of ABP 798 vs its reference product, Rituximab at a dose of 375 mg/m2 (IV, qw) for 4wks. followed by dosing at weeks 12 […]readmore
Shots: The P-I/III (NCT02792699) study involves assessing of ABP 798 vs Rituxan (rituximab, IV) in 311 patients in the ratio (1:1:1) with moderate-to-severe RA, evaluating safety, efficacy, and PK for 48 wks. The […]readmore